How many clinical trials are studying Tremelimumab?

9 recruiting trials in our tracked data involve Tremelimumab.

What conditions is Tremelimumab being studied for?

In our tracked recruiting trials, Tremelimumab is being studied in trials for Lung cancer, Colorectal Cancer, Pancreatic Cancer.

Tremelimumab: clinical trials recruiting now

Q: Is Tremelimumab FDA-approved?

Yes. According to the FDA drug label available through openFDA, Tremelimumab is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Tremelimumab appears in the FDA drug-label database. Marketed as IMJUDO.
Drug class: CTLA-4-directed Blocking Antibody (FDA established pharmacologic class)
Mechanism of action: CTLA-4-directed Antibody Interactions (as stated on the FDA label)

FDA-approved use

IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) 1.1 Hepatocellular Carcinoma IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). 1.2 Non-Small Cell Lung Cancer (NSCLC) IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

FDA label via openFDA

Phase breakdown

Early Phase 1 1 Phase 1 2 Phase 2 6 Phase 3 1

Conditions being studied

Condition	Trials
Lung cancer · Tremelimumab for Lung cancer	4
Colorectal Cancer	2
Pancreatic Cancer	2
Anatomic Stage IV Breast Cancer AJCC v8	1
Biliary Tract Cancer	1
Borderline Resectable Pancreatic Ductal Adenocarcinoma	1
Breast cancer	1
Carcinoma, Non-Small Cell Lung	1
Cholangiocarcinoma	1
Endometrial Cancer	1
Esophageal Adenocarcinoma	1
Gastric Cancer	1
HIV	1
Hepatocellular Cancer	1
Hepatocellular Carcinoma	1

Recruiting trials involving Tremelimumab

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
NCT07391670 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
NCT03539822 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
NCT04499053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
NCT05451043 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
NCT04585490 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Single cEll pRofiling PErsistaNce To ImmuNothErapy
NCT06680739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT04005690 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations

Common questions

Is Tremelimumab FDA-approved?

Yes, marketed as IMJUDO.

How many recruiting trials involve Tremelimumab?

9 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.